Literature DB >> 3133938

Cardiopulmonary exercise testing in congestive heart failure.

P A McElroy1, J S Janicki, K T Weber.   

Abstract

Cardiopulmonary exercise testing includes the monitoring of respiratory gases and airflow to determine oxygen uptake, carbon dioxide (CO2) production, respiratory rate, tidal volume, and minute ventilation during a graded maximal exercise test. A plateau in oxygen uptake, which occurs despite an increase in work load, and which is termed maximal oxygen uptake (VO2 max), correlates with the maximal exercise cardiac output and can therefore be used to grade the severity of heart failure. The anaerobic threshold occurs at 60 to 70% of VO2 max and is another indicator of the severity of heart failure and, when attained, indicates that the patient is close to performing a maximal test. We have found VO2 max and anaerobic threshold to be objective measures of efficacy of both investigational and noninvestigational therapy in patients with heart failure. A pulmonary limitation to exercise can be identified by the failure to attain anaerobic threshold or VO2 max, as well as exhaustion of the ventilatory reserve, as estimated by maximal voluntary ventilation. Thus, cardiopulmonary exercise testing can be used to (1) grade the severity of heart failure, (2) objectively follow the response to therapy, and (3) differentiate a cardiac from a pulmonary limitation to exercise.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133938     DOI: 10.1016/s0002-9149(88)80083-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  [Not Available].

Authors:  B Schwaab; M Kindermann; M Berg; O Kusch; G Fröhlig; H Schieffer
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2000-01

2.  Preserved cardiorespiratory function and NT-proBNP levels before and during exercise in patients with recent onset of rheumatoid arthritis: the clinical challenge of stratifying the patient cardiovascular risks.

Authors:  A Zoli; S Bosello; G Comerci; N Galiano; A Forni; F Loperfido; G F Ferraccioli
Journal:  Rheumatol Int       Date:  2015-11-19       Impact factor: 2.631

3.  A randomized pilot trial of remote ischemic preconditioning in heart failure with reduced ejection fraction.

Authors:  Michael A McDonald; Juarez R Braga; Jing Li; Cedric Manlhiot; Heather J Ross; Andrew N Redington
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

4.  A predictor of aerobic threshold for patients with heart failure with reduced ejection fraction.

Authors:  Sawako Yamamoto; Yorimitsu Furukawa; Seiji Fukushima; Osamu Nitta
Journal:  J Phys Ther Sci       Date:  2018-09-04

5.  "TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure".

Authors:  Jaime S Horton; Takuya Shiraishi; Naghum Alfulaij; Andrea L Small-Howard; Helen C Turner; Tatsuki Kurokawa; Yasuo Mori; Alexander J Stokes
Journal:  Channels (Austin)       Date:  2019-12       Impact factor: 2.581

6.  Outcomes of Cardiac Contractility Modulation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Authors:  Ramy Mando; Akshay Goel; Fuad Habash; Marwan Saad; Karam Ayoub; Srikanth Vallurupalli; Waddah Maskoun
Journal:  Cardiovasc Ther       Date:  2019-06-17       Impact factor: 3.023

7.  Mechanism of Dyspnea during Exercise in Children with Corrected Congenital Heart Disease.

Authors:  Mehdi Chlif; Mohamed Mustapha Ammar; Noureddine Ben Said; Levushkin Sergey; Said Ahmaidi; Fawaz Alassery; Habib Hamam
Journal:  Int J Environ Res Public Health       Date:  2021-12-23       Impact factor: 3.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.